Other targets, such as anti-angiogenesis, EGFR amp, WNT/a-catenin, Hedgehog, and HGF/c-MET, have been reported in cholangiocarcinoma, but most of these pathways can be found in most tumour types, and multiple previous clinical trials in cholangiocarcinoma have shown limited effectiveness. This evidence concerns the gene EGFR and cholangiocarcinoma.